Skip to main content
Fig. 3 | BMC Ophthalmology

Fig. 3

From: A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Fig. 3

BCVA improvement and reduction in CRT from baseline at Month 12 by number of injections administered. *P = 0.0252;**P < 0.001. indicates mean number of injections. BCVA: baseline, > 3 injections n = 85, ≤3 injections n = 66; Month 12, > 3 injections n = 57, ≤3 injections n = 36. CRT: baseline, > 3 injections n = 84, ≤3 injections n = 67; Month 12, > 3 injections n = 53, ≤3 injections n = 32. BCVA, best-corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment for Diabetic Retinopathy Study; n, number of patients; SD, standard deviation

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us